Re: International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy

Journal of the National Cancer Institute

Volumn 102, Issue 3, 2010, Pages 207-

  Köstler, Wolfgang J ^a   Brodowicz, Thomas ^a,b   Zielinski, Christoph C ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Central European Cooperative Oncology Group   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL DECISION MAKING; CONSENSUS; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; LETTER; MENOPAUSE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 76349092029     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp483     Document Type: Letter

References (7)

1. Cardoso f, Bedard pl, Winer Ep, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17):1174-1181.
2. nCCn Clinical practice guidelines in oncology\-Breast Cancer V.2.08. http://www.nccn.org/professionals/physician-gls/pdf/ breast.pdf. Accessed november 8, 2009.
3. Beslija S, Bonneterre J, Burstein HJ, et al. Consensus on medical treatment of metastatic breast cancer (statement for Central European Cooperative oncology group). Breast Cancer Res Treat. 2003;81(suppl 1):1-7.
4. Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007;18(2): 215-225.
5. Beslija S, Bonneterre J, Burstein HJ, et al. third consensus on medical treatment of met-astatic breast cancer. Ann Oncol. 2009;20(11): 1771-11185
6. Tomova A, Brodowicz t, tzekova V, et al. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine [abstract 1106]. J Clin Oncol. 2008;26(suppl).
7. tomova A, Bartsch R, Brodowicz t, et al. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcit-abine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative oncology group (CECog) [published online ahead of print September 19, 2009]. Breast Cancer Res Treat. 2010;119(1):169-176.